Moreover, amplification of genes associated with SRC effector networks such as PI3K/AKT/mTor and FAK are reported in 17% and 6% of pancreatic tumors, respectively [23–25], while aberrant expression of integrin signaling components that activate SRC are observed in 67% of pancreatic tumors [34]. This evidence concerns the gene MTOR and pancreatic neoplasm.